Bionano Genomics (BNGO) Capital Leases (2021 - 2026)

Bionano Genomics' Capital Leases history runs 6 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Capital Leases fell 1.79% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 1.79% YoY), while the FY2025 annual figure was $3.5 million, down 1.67% from the prior year.
• Capital Leases came in at $3.5 million for Q1 2026 at Bionano Genomics, roughly flat from $3.5 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $3.6 million in Q1 2022 to a low of $3.5 million in Q1 2026.
• A 5-year average of $3.6 million and a median of $3.6 million in 2024 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases decreased 0.63% in 2022 and retreated 1.79% in 2026, its largest moves.
• Bionano Genomics' Capital Leases stood at $3.6 million in 2022, then retreated by 0.94% to $3.6 million in 2023, then retreated by 1.28% to $3.5 million in 2024, then fell by 1.67% to $3.5 million in 2025, then retreated by 0.49% to $3.5 million in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $3.5 million, $3.5 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison